|
시장보고서
상품코드
1890927
유전자 침묵 시장 : 유형별, 컴포넌트별, 용도별, 치료 영역별, 기술별, 전달 방법별, 최종사용자별, 지역별Gene Silencing Market, By Type, By Component, By Application, By Therapeutic Area, By Technology, By Delivery Method, By End User, By Geography |
||||||
유전자 침묵 시장은 2025년에 112억 1,000만 달러로 추정되며, 2032년까지 278억 8,000만 달러에 달할 것으로 예측됩니다. 2025-2032년 CAGR 13.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 커버 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 112억 1,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 13.90% | 2032년 예측 : | 278억 8,000만 달러 |
세계 유전자 침묵 시장은 생명공학 및 제약 산업에서 빠르게 진화하고 있는 분야로, 특정 유전자를 표적으로 삼아 그 발현을 조절하는 혁신적인 치료 접근법을 포함하고 있습니다. 유전자 침묵(RNA 간섭(RNAi) 또는 유전자 녹다운이라고도 함)은 작은 간섭 RNA(siRNA), 마이크로 RNA(miRNA), 안티센스 올리고뉴클레오티드, CRISPR 기반 기술 등 다양한 연구 기법을 통해 표적 유전자의 발현을 억제 또는 감소시키는 첨단 분자 메커니즘을 수반합니다. 억제하거나 감소시키는 첨단 분자 메커니즘을 수반합니다.
이 시장은 정밀의료 접근이 필요한 유전질환, 암, 심혈관질환, 신경질환 증가로 인해 큰 모멘텀을 얻고 있습니다. 이 기술은 질병 원인 유전자를 특이적으로 침묵시키면서 오프타겟 효과를 최소화하여 기존에는 치료가 어려웠던 표적 치료에 전례 없는 기회를 제공합니다. 주요 제약사, 생명공학 기업, 연구기관들은 차세대 치료제 개발을 위해 유전자 침묵 플랫폼에 많은 투자를 하고 있습니다. 본 시장은 유전자 침묵제의 안정성과 생체 이용률을 높이는 지질 나노입자, 바이러스 벡터, 컨쥬게이트 기반 전달 메커니즘 등 다양한 전달 시스템을 포괄하고 있습니다. 규제 프레임워크가 계속 진화하고 이러한 혁신적인 치료법을 지지하는 가운데, 유전자 침묵 시장은 여러 치료 영역에서 치료 패러다임을 바꾸고, 전 세계에서 중요한 상업적 기회를 창출하며, 미충족 의료 수요를 충족시킬 수 있는 위치에 있습니다.
시장 역학
세계 유전자 침묵 시장은 몇 가지 강력한 촉진요인에 의해 주도되고 있습니다. 전 세계에서 증가하는 유전성 질환 및 만성질환의 유병률은 질병 원인 유전자를 특이적으로 조절할 수 있는 표적치료제에 대한 큰 수요를 창출하고 있습니다. 패티실란, 기보실란과 같은 승인된 RNAi 치료제의 성공 사례가 증가하면서 유전자 침묵 기술의 임상적 잠재력을 입증하고 있으며, 제약 산업 전반에 걸쳐 더 많은 투자와 개발 활동을 촉진하고 있습니다. 전달 시스템, 특히 지질 나노입자 및 조직 특이적 표적화 메커니즘의 기술적 진보는 치료 효과를 크게 향상시키고 부작용을 감소시켰습니다. 이를 통해 유전자 침묵화 접근법은 임상 적용에 대한 실현 가능성이 더욱 높아졌습니다. 그러나 시장은 또한 뚜렷한 제약에 직면하고 있습니다. 여기에는 유전자 침묵 요법에 따른 높은 개발 비용, 전문 시설과 전문 지식이 필요한 복잡한 제조 공정, 개발 기간을 연장하고 기업의 재무적 위험을 증가시키는 엄격한 규제 요건 등이 포함됩니다.
또한 표적 외 효과, 면역원성 우려, 특정 조직에 대한 전달 효율 등의 문제는 여전히 대중화를 위한 기술적 장벽으로 남아 있습니다. 이러한 제약에도 불구하고 희귀질환을 넘어 심혈관질환, 대사성 질환, 종양학 분야 등 보다 일반적인 질환에 대한 적용 확대로 큰 기회가 창출되고 있습니다. 맞춤의료와 정밀치료에 대한 관심이 높아지면서 유전자 침묵 기술에 유리한 조건이 조성되고 있습니다. 한편, 제약회사와 생명공학 기업 간의 협력 강화는 지식 공유를 촉진하고 제품 개발을 가속화하고 있습니다. 또한 신흥 시장에서는 헬스케어 인프라가 정비되고, 혁신적 치료법에 대한 규제 경로가 확립되고 있으며, 미개발 가능성이 확대되고 있습니다. 이를 통해 유전자 침묵 시장은 다양한 치료 영역에서 지속적인 성장과 혁신을 이룰 수 있는 기반이 마련되었습니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR)을 제시하는 세계 유전자 침묵 시장에 대한 상세한 분석을 제공합니다.
- 또한 다양한 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보도 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 유전자 침묵 시장의 주요 업체를 프로파일링합니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 유전자 침묵 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 유전자 침묵 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 유전자 침묵 시장 : 유형별, 2020-2032년
- 전사 후
- 전사
제5장 세계의 유전자 침묵 시장 : 컴포넌트별, 2020-2032년
- 제품(시약, 키트, 기기)
- 서비스
제6장 세계의 유전자 침묵 시장 : 용도별, 2020-2032년
- 기능 유전체학
- Drug Discovery 타겟 검증
- 질환 모델
- 치료법개발
- 바이오 생산 최적화
제7장 세계의 유전자 침묵 시장 : 치료 영역별, 2020-2032년
- 종양학
- 유전성 질환
- 감염증
- 심혈관 질환
- 신경질환
- 대사성 질환
- 자가면역질환
- 안과 질환
제8장 세계의 유전자 침묵 시장 : 기술별, 2020-2032년
- RNA 간섭(RNAi)
- 안티센스 올리고뉴클레오티드(ASO)
- CRISPR 기반 유전자 침묵
- siRNA
- shRNA
- 마이크로 RNA
- DNA 메틸화에 기반한 침묵
- 히스톤 수식에 기반한 침묵
제9장 세계의 유전자 침묵 시장 : 전달 방법별, 2020-2032년
- 바이러스 벡터에 의한 전달
- 비바이러스 벡터에 의한 전달
- 지질 나노입자
- 전기 천공법
- 물리적 방법(현미경하주사법, 유전자 암, 초음파)
제10장 세계의 유전자 침묵 시장 : 최종사용자별, 2020-2032년
- 제약·바이오테크놀러지 기업
- 학술·연구기관
- 수탁 조사기관(CRO)
- 진단 검사 기관
- 정부 및 비영리 연구기관
제11장 세계의 유전자 침묵 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Danaher Corporation
- Bio Rad Laboratories Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Arbutus Biopharma Corporation
- Wave Life Sciences Ltd.
- Moderna Inc.
- BioNTech SE
제13장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고 문헌 및 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Gene Silencing Market is estimated to be valued at USD 11.21 Bn in 2025 and is expected to reach USD 27.88 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 11.21 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 13.90% | 2032 Value Projection: | USD 27.88 Bn |
The global gene silencing market represents a rapidly evolving segment within the biotechnology and pharmaceutical industries, encompassing innovative therapeutic approaches that target specific genes to modulate their expression. Gene silencing, also known as RNA interference (RNAi) or gene knockdown, involves sophisticated molecular mechanisms that prevent or reduce the expression of target genes through various methodologies including small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, and CRISPR-based technologies.
This market has gained substantial momentum due to increasing prevalence of genetic disorders, cancer, cardiovascular diseases, and neurological conditions that require precision medicine approaches. The technology offers unprecedented opportunities for treating previously undruggable targets by specifically silencing disease-causing genes while minimizing off-target effects. Major pharmaceutical companies, biotechnology firms, and research institutions are heavily investing in gene silencing platforms to develop next-generation therapeutics. The market encompasses various delivery systems including lipid nanoparticles, viral vectors, and conjugate-based delivery mechanisms that enhance the stability and bioavailability of gene silencing agents. As regulatory frameworks continue to evolve and support these innovative therapies, the gene silencing market is positioned to transform treatment paradigms across multiple therapeutic areas, driving significant commercial opportunities and addressing critical unmet medical needs globally.
Market Dynamics
The global gene silencing market is propelled by several compelling drivers, including the escalating prevalence of genetic disorders and chronic diseases worldwide, which creates substantial demand for targeted therapeutic interventions that can specifically modulate disease-causing genes. The increasing success of approved RNAi therapeutics such as patisiran and givosiran has validated the clinical potential of gene silencing technologies, encouraging greater investment and development activities across the pharmaceutical industry. Technological advancements in delivery systems, particularly lipid nanoparticles and tissue-specific targeting mechanisms, have significantly improved the therapeutic efficacy and reduced adverse effects, making gene silencing approaches more viable for clinical applications. However, the market faces notable restraints including high development costs associated with gene silencing therapies, complex manufacturing processes requiring specialized facilities and expertise, and stringent regulatory requirements that extend development timelines and increase financial risks for companies.
Additionally, challenges related to off-target effects, immunogenicity concerns, and delivery efficiency to specific tissues continue to pose technical barriers for widespread adoption. Despite these constraints, substantial opportunities emerge from expanding applications beyond rare diseases into more prevalent conditions such as cardiovascular diseases, metabolic disorders, and oncology indications. The growing emphasis on personalized medicine and precision therapeutics creates favorable conditions for gene silencing technologies, while increasing collaborations between pharmaceutical companies and biotechnology firms facilitate knowledge sharing and accelerate product development. Furthermore, emerging markets present untapped potential as healthcare infrastructure improves and regulatory pathways for innovative therapies become more established, positioning the gene silencing market for sustained growth and innovation across diverse therapeutic landscapes.
Key Features of the Study
- This report provides in-depth analysis of the global gene silencing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global gene silencing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Danaher Corporation, Bio Rad Laboratories Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arbutus Biopharma Corporation, Wave Life Sciences Ltd., Moderna Inc., and BioNTech SE
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global gene silencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gene silencing market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Post-Transcriptional
- Transcriptional
- Component Insights (Revenue, USD Bn, 2020 - 2032)
- Product (Reagents, Kits, Instruments)
- Services
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Functional Genomics
- Drug Target Validation
- Disease Modeling
- Therapeutic Development
- Bioproduction Optimization
- Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Genetic Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Metabolic Disorders
- Autoimmune Disorders
- Ophthalmic Diseases
- Technology Insights (Revenue, USD Bn, 2020 - 2032)
- RNA Interference (RNAi)
- Antisense Oligonucleotides (ASOs)
- CRISPR-based Gene Silencing
- siRNA
- shRNA
- miRNA
- DNA Methylation-based Silencing
- Histone Modification-based Silencing
- Delivery Method Insights (Revenue, USD Bn, 2020 - 2032)
- Viral Vector Delivery
- Non-Viral Vector Delivery
- Lipid Nanoparticles
- Electroporation
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Pharmaceutical and Biotech Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Government and Non-Profit Research Bodies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Danaher Corporation
- Bio Rad Laboratories Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Arbutus Biopharma Corporation
- Wave Life Sciences Ltd.
- Moderna Inc.
- BioNTech SE
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Gene Silencing Market, By Type
- Global Gene Silencing Market, By Component
- Global Gene Silencing Market, By Application
- Global Gene Silencing Market, By Therapeutic Area
- Global Gene Silencing Market, By Technology
- Global Gene Silencing Market, By Delivery Method
- Global Gene Silencing Market, By End User
- Global Gene Silencing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Gene Silencing Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Post-Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Gene Silencing Market, By Component, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Product (Reagents, Kits, Instruments)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Gene Silencing Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Functional Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drug Target Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Therapeutic Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bioproduction Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Gene Silencing Market, By Therapeutic Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Gene Silencing Market, By Technology, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- RNA Interference (RNAi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antisense Oligonucleotides (ASOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- CRISPR-based Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- siRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- shRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- miRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- DNA Methylation-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Histone Modification-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Gene Silencing Market, By Delivery Method, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lipid Nanoparticles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Electroporation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Gene Silencing Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and Biotech Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Government and Non-Profit Research Bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Gene Silencing Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bio Rad Laboratories Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Silence Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dicerna Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arbutus Biopharma Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Wave Life Sciences Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moderna Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
